Big pharma might cut R&D, delay new drugs if more generics with pharmacare

ANDY BLATCHFORD | April 15, 2019

article image
Brand-name drug companies could put off introducing new medicine in Canada and scale back research here if the country makes a major shift to cheaper generic alternatives under a national pharmacare plan, according to an internal federal analysis. The concerns were included last year in a briefing document for federal Finance Minister Bill Morneau that explored the feasibility and costs of a pharmacare program. Pharmacare is shaping up as a key campaign issue in the October election, particularly for the Liberals. The Finance Department's analysis was created a few days before Morneau's 2018 budget officially launched an advisory group on Canada-wide pharmacare, which the Liberals say will cut costs and improve Canadians' access to prescription drugs. The document said more information is needed to fully understand how national pharmacare would affect drug spending in Canada — and what it would mean for revenues and business operations for the domestic pharmaceutical industry.

Spotlight

Aerobit Health Limited

There is a need for patients to remember to adhere with their treatments and keep doctors in the loop with critical data. Aerobit is platform of smart hardware and software making managing asthma easier and more effective than ever. Aerobit’s mission is to be at the epicenter of improving Asthma care through a revolution in digital healthcare. Aerobit is a digital health startup building an asthma care platform with a Smart Inhaler Device at the epicenter. Our aim is to improve the quality of life of millions of asthma sufferers in the UK and reduce the risk of unnecessary fatalities due to this common chronic disease.

OTHER ARTICLES

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 4, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

5 Pharma Trends and Their Impact on Packaging

Article | February 27, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Global Antiviral Drugs Market Growth: Is Antiviral Drug the Best Coronavirus Treatment?

Article | April 9, 2020

The global antiviral drugs market has witnessed a rapid surge in demand due to the ongoing Covid-19 pandemic worldwide. So is antiviral drug the best coronavirus treatment? It is still too early to have that conclusion as many medical research and clinical trials are still trying to find the effectiveness and potential side effects of using antiviral drugs to treat coronavirus. But experts believe that antiviral drug might be the best hope for reduce the coronavirus transmission around the world at this stage. However, due to the current difficult situation of the supply chain in many lockdown countries and regions, there is a global shortage on the antiviral drugs supply. With researchers and manufacturers working hard to find and provide effective coronavirus treatment, it is expected that the global antiviral drugs market will have a significant growth over the near future. Antiviral drugs are a type of medication used specifically for treating viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza.

Read More

Spotlight

Aerobit Health Limited

There is a need for patients to remember to adhere with their treatments and keep doctors in the loop with critical data. Aerobit is platform of smart hardware and software making managing asthma easier and more effective than ever. Aerobit’s mission is to be at the epicenter of improving Asthma care through a revolution in digital healthcare. Aerobit is a digital health startup building an asthma care platform with a Smart Inhaler Device at the epicenter. Our aim is to improve the quality of life of millions of asthma sufferers in the UK and reduce the risk of unnecessary fatalities due to this common chronic disease.

Events